Clinicians Are Calling for a Smarter, Faster Approach to Treatment-Resistant Depression
A new analysis published in Psychiatric Times in April 2026 is pushing the field of treatment-resistant depression (TRD) toward a more data-driven standard of care—one that directly affects how ketamine and esketamine are prescribed, monitored, and adjusted. The paper examines the side effect profiles and discontinuation rates associated with NMDA receptor antagonists, the drug class that includes both IV ketamine and intranasal esketamine (Spravato), and concludes that clinicians can and should be moving faster: optimizing doses more aggressively, switching treatment approaches sooner when response plateaus, and systematically tracking outcomes like PHQ-9 scores alongside side effect burden.
For patients navigating online ketamine therapy in 2026, this research arrives at a meaningful moment. The telehealth ketamine space has matured considerably, but variability in monitoring protocols, follow-up frequency, and dose escalation practices remains a real concern. Understanding what the clinical literature is now recommending—and how to evaluate whether your provider is meeting that standard—can meaningfully improve your odds of reaching remission.
What the Research Actually Found
The Psychiatric Times analysis synthesizes clinical data on how patients tolerate NMDA antagonists over time and why many discontinue treatment before experiencing full benefit. The key findings center on a few consistent themes:
- Dissociation and perceptual side effects are the most commonly cited reasons for discontinuation, but they are often dose-dependent and manageable with structured titration.
- Discontinuation rates are meaningfully higher when providers fail to proactively address side effects early in the treatment course—suggesting that attentive follow-up during initial sessions is not optional, it's protective.
- PHQ-9 tracking (a standardized depression severity questionnaire) is identified as an underutilized but essential tool for knowing when to hold a dose, escalate, or pivot to a different approach entirely.
- Dose optimization is being done too slowly in many clinical settings. The authors argue that hesitancy around titration is leaving patients in a subtherapeutic range longer than necessary, delaying remission and increasing dropout.
These are not abstract findings. They describe what happens in real clinics—including virtual ones—when follow-up is infrequent, when side effect conversations are cursory, or when providers lack a structured protocol for escalation.
Why This Matters for Online Ketamine Patients Specifically
Telehealth ketamine has democratized access to a treatment that was once confined to expensive infusion suites, and that's a genuine win for patients with TRD who have exhausted conventional antidepressants. But the convenience of at-home treatment introduces specific risks that the Psychiatric Times findings put in sharp relief.
When you're treating at home with oral or sublingual ketamine, the clinical relationship is almost entirely asynchronous. Your provider isn't in the room with you. Side effects that would be immediately visible in an infusion clinic—dysphoria, elevated heart rate, dissociative distress—have to be self-reported. That places a higher burden on both the patient and the provider's follow-up infrastructure.
The new guidance effectively asks: does your provider have a system for catching early warning signs? Are they tracking your PHQ-9 at regular intervals and actually adjusting your care based on the results? Are they willing to move quickly—either escalating your dose or reconsidering the approach—if you're not responding after an appropriate trial?
If the answer to any of those questions is unclear, that's worth pressing your provider on before continuing or starting treatment.
How to Evaluate Your Provider Against This Standard
The practical implications of this research can be distilled into a checklist for anyone currently in—or considering—online ketamine therapy:
- Structured intake screening matters. A provider who doesn't assess cardiovascular history, substance use, dissociation vulnerability, or baseline depression severity before prescribing isn't positioned to manage your side effect risk appropriately.
- Follow-up should be scheduled, not optional. The research underscores that proactive monitoring—not just a patient portal where you can message if something goes wrong—is what keeps discontinuation rates low. Ask specifically how often you'll have a synchronous check-in with a clinician.
- PHQ-9 or equivalent outcome tracking should be standard. If your provider isn't asking you to complete a validated depression scale at regular intervals, they have no objective basis for deciding whether to adjust your dose.
- Dose flexibility is a feature, not a risk. One of the paper's core arguments is that under-dosing is a significant problem. A quality provider should have a clear, documented protocol for titration—and be willing to explain it to you.
- Side effect management should be discussed upfront. Dissociation, nausea, and blood pressure changes are predictable. You should receive guidance on what to expect and when to report, before your first session—not after something goes wrong.
Key Takeaway for Patients
New clinical guidance confirms that slow dose adjustment and inconsistent monitoring are primary drivers of early treatment discontinuation in NMDA-based therapies. If your online ketamine provider isn't tracking PHQ-9 scores, scheduling regular check-ins, and following a clear titration protocol, you may be getting less than the standard of care the field now recommends. Before starting or continuing treatment, ask your provider directly how they handle dose optimization and side effect monitoring—the answer tells you a great deal about the quality of care you'll receive.
The Bigger Picture: Data-Driven Care Is Becoming the Expectation
What makes this Psychiatric Times analysis worth attention beyond its specific findings is what it signals about where clinical standards are heading. The era of ketamine as a loosely monitored, largely experimental intervention is giving way to a more rigorous framework—one where outcomes are tracked, side effects are systematically managed, and treatment decisions are made on evidence rather than intuition.
That's a good thing for patients. It means the bar for what constitutes adequate telehealth ketamine care is rising, and providers who don't keep pace will increasingly stand out as outliers. As you evaluate online ketamine options in 2026, use that rising standard as your benchmark. The clinics and providers building genuine monitoring infrastructure—not just prescribing and stepping back—are the ones aligned with where the evidence is pointing.
Read the original analysis at Psychiatric Times.
Share